Unibest

Pharmaceutical intermediates

Infigratinib Intermediates

1 pharmaceutical intermediate for Infigratinib. Indication: Achondroplasia.

提交项目All intermediates

About Infigratinib

Originator
Novartis AG
Indication
Achondroplasia
Approved Date
05/28/2021
NCE Patent
05/28/2026
DS/DP
08/06/2028

Available intermediates

1 intermediate currently listed for Infigratinib. Request specifications, documentation or a quotation for any item below.

Infigratinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
2,6-Dichloro-3,5-dimethoxyaniline872509-56-3//

Other programs under I

Ibrutinib/ Zanubrutinib IguratimodImatinibImeglimin hydrochlorideIndacaterol MaleateIpatacopan HydrochlorideIpragliflozinIrinotecan

Building toward Infigratinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →